Rasa has launched two coffee alternative mixes with adaptogenic herbs and mushrooms instead of caffeine, the Classic Rasa and Café Rasa.
Rasa CEO and founder, Lopa van der Mersch, said Classic Rasa, which is made of roasted chicory, burdock root, and date seed to create a dark, rich, and sweet blend, is the most coffee-like alternative out there.
It also has adaptogens: red Asian ginseng, cordyceps, rhodiola, gynostemma, shatavari, and maca.
Meanwhile, Café Rasa blends freeze-fried coffee from Chiapas, Mexico, with adaptogens that are said to soften coffee’s downsides whilst supplementing caffeine’s fatigue-fighting abilities.
According to van der Mersch, the two new mixes open new channels of distribution and provide everyone with the opportunity to drink Rasa.
Co-founder, Ben LeVine, added that their process includes brewing the herbs over several hours like a standard decoction, then drying it and granulating it to produce a supremely delicious, dissolvable, and bioavailable mix.


American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Why a ‘rip-off’ degree might be worth the money after all – research study
Parents abused by their children often suffer in silence – specialist therapy is helping them find a voice
Australian Household Spending Dips in December as RBA Tightens Policy
The Beauty Beneath the Expressway: A Journey from Self to Service
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Washington Post Publisher Will Lewis Steps Down After Layoffs
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 



